Get the Stockscreener App
6.99
1.30%
0.09
After Hours:
6.99
Evolus Inc stock is traded at $6.99, with a volume of 643.60K.
It is up +1.30% in the last 24 hours and up +4.80% over the past month.
Evolus Inc is a performance beauty company offering medical aesthetic products in the cash-pay aesthetic market. The company's commercially available products represent two product categories within medical aesthetics: injectable neurotoxins and injectable hyaluronic acid (HA) gels. Its commercial products are: Jeuveau, a proprietary 900-kilodalton, purified botulinum toxin type A formulation indicated for the temporary improvement in the appearance of moderate to severe frown lines, in adults; and Evolysse, a collection of injectable HA gels that utilizes first-generation cold technology. The line includes several products, including mid face, nasolabial folds, lips, and eyes. Geographically, the company currently has operations in the United States, Canada, Europe, and Australia.
See More
Previous Close:
$6.90
Open:
$6.88
24h Volume:
643.60K
Relative Volume:
0.78
Market Cap:
$460.32M
Revenue:
$301.79M
Net Income/Loss:
$-43.42M
P/E Ratio:
-10.43
EPS:
-0.6705
Net Cash Flow:
$-44.87M
1W Performance:
-1.96%
1M Performance:
+4.80%
6M Performance:
+18.27%
1Y Performance:
-24.60%
1-Day Range:
$6.85
$7.08
1-Week Range:
$6.695
$7.13
52-Week Range:
$3.86
$10.20
Evolus Inc Stock (EOLS) Company Profile
Name
Evolus Inc
Sector
Phone
(949) 284-4555
Address
520 NEWPORT CENTER DRIVE, NEWPORT BEACH
Compare EOLS vs TAK, HLN, TEVA, ZTS, UTHR
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
EOLS
Evolus Inc
|
6.99 | 457.03M | 301.79M | -43.42M | -44.87M | -0.6705 |
TAK
Takeda Pharmaceutical Co Adr
|
16.89 | 50.65B | 29.91B | 1.30B | 3.49B | 0.4056 |
HLN
Haleon Plc Adr
|
9.72 | 41.09B | 14.54B | 2.22B | 2.58B | 0.4871 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
35.29 | 39.45B | 17.53B | 1.58B | 444.18M | 1.3457 |
ZTS
Zoetis Inc
|
75.42 | 30.13B | 9.51B | 2.64B | 2.14B | 6.0361 |
UTHR
United Therapeutics Corp
|
547.25 | 23.00B | 3.17B | 1.29B | 1.01B | 27.09 |
Evolus Inc Stock (EOLS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-06-25 | Downgrade | Needham | Buy → Hold |
| Apr-17-25 | Initiated | BTIG Research | Buy |
| Jan-29-24 | Upgrade | Barclays | Equal Weight → Overweight |
| Jun-23-22 | Initiated | Needham | Buy |
| May-12-22 | Upgrade | Barclays | Underweight → Equal Weight |
| Jan-20-22 | Upgrade | Truist | Hold → Buy |
| May-06-21 | Upgrade | Mizuho | Neutral → Buy |
| Apr-08-21 | Reiterated | H.C. Wainwright | Buy |
| Feb-24-21 | Downgrade | Truist | Buy → Hold |
| Jul-07-20 | Downgrade | Mizuho | Buy → Neutral |
| Feb-06-20 | Resumed | Mizuho | Buy |
| Nov-26-19 | Initiated | SVB Leerink | Outperform |
| Sep-05-19 | Resumed | Mizuho | Buy |
| Jun-28-19 | Initiated | Wells Fargo | Market Perform |
| Jun-11-19 | Initiated | Barclays | Underweight |
| Mar-20-19 | Initiated | SunTrust | Buy |
| Feb-14-19 | Initiated | H.C. Wainwright | Buy |
| Jan-29-19 | Initiated | Stifel | Buy |
View All
Evolus Inc Stock (EOLS) Latest News
Evolus (EOLS) price target decreased by 11.11% to 14.96 - MSN
Evolus Q1 2026 earnings preview - MSN
Price to sales forward of Evolus, Inc. Common Stock – NASDAQ:EOLS - TradingView
Enterprise value to revenue forward of Evolus, Inc. Common Stock – NASDAQ:EOLS - TradingView
Evolus, Inc. Actuals & Estimates (NASDAQ:EOLS) - TradingView
EVL Forecast — Price Target — Prediction for 2027 - TradingView
EOLS Forecast — Price Target — Prediction for 2027 - TradingView
EOLS News | EVOLUS INC (NASDAQ:EOLS) - ChartMill
Evolus Inc (EOLS) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Evolus, Inc.(NasdaqGM: EOLS) added to S&P Pharmaceuticals Select Industry Index - marketscreener.com
Is Evolus (EOLS) Finally Turning the Corner on Profitability - Kavout | AI
Evolus Inc (EOLS) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Evolus Inc (EOLS) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Evolus Inc (EOLS) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Evolus Inc (EOLS) Valuation: PE, PB & Fair Value Analysis - TradingKey
Evolus Inc (EOLS) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Evolus Inc (EOLS) Institutional Confidence - TradingKey
Evolus Inc (EOLS) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Evolus Inc (EOLS) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
BTIG Maintains Evolus(EOLS.US) With Buy Rating, Maintains Target Price $13 - Moomoo
EOLS Reiterated by BTIG -- Price Target Maintained at $13.00 - GuruFocus
[EFFECT] Evolus, Inc. SEC Filing - Stock Titan
Understanding the Setup: (EOLS) and Scalable Risk - Stock Traders Daily
Evolus shareholders re-elect directors and approve executive compensation By Investing.com - Investing.com South Africa
Evolus shareholders re-elect directors and approve executive compensation - Investing.com
Evolus (EOLS) shareholders approve directors, auditor and say-on-pay at 2026 meeting - Stock Titan
Evolus, Inc. (EOLS) reports Q1 loss, tops revenue estimates - MSN
Mizuho Securities Maintains Evolus(EOLS.US) With Buy Rating, Maintains Target Price $15 - Moomoo
Evolus (NASDAQ: EOLS) registers $250M shelf; $195.5M unsold re‑registered - Stock Titan
EOLS: Virtual Meeting with Management Scheduled on June 11 - GuruFocus
AEON Biopharma to Present Data Demonstrating Structural and Functional Comparability of ABP-450 to BOTOX® at the 68th Annual Scientific Meeting of the American Headache Society - GlobeNewswire Inc.
Evolus (EOLS) Jefferies Global Healthcare Conference 2026 Summary - Quartr
The Technical Signals Behind (EOLS) That Institutions Follow - Stock Traders Daily
Evolus (EOLS) Q2 2025 Earnings Call Transcript - AOL.com
Evolus Shareholder Notice - TMX Newsfile
Evolus Update - TMX Newsfile
Evolus Class Action Reminder - TMX Newsfile
Evolus Shareholder Alert - TMX Newsfile
Earnings call transcript: Evolus Inc Q1 2026 misses EPS forecast, stock rises - Investing.com Nigeria
EOLSEvolus Inc Stock Price and Quote - Finviz
Precision Trading with Evolus Inc. (EOLS) Risk Zones - Stock Traders Daily
Evolus to Participate in The Jefferies Global Healthcare Conference - Business Wire
Evolus To Roll Out Estyme Injectable Hyaluronic Acid Fillers in Europe - The Dermatology Digest
TradingKey - TradingKey
Evolus Completes Key NUCEIVA Safety Study, Easing Risk for Aesthetic Toxin Investors - TipRanks
Evolus (EOLS) to Launch Estyme Injectable Collection in Europe - GuruFocus
Evolus to launch Estyme dermal filler line in Europe on May 16 - Investing.com UK
Evolus to Launch Estyme Dermal Fillers in Europe - Orange County Business Journal
Evolus to launch Estyme dermal filler line in Europe on May 16 By Investing.com - Investing.com South Africa
Evolus, Inc. Launches Estyme Injectable Hyaluronic Acid Gels Collection in Europe - marketscreener.com
Evolus launches Estyme in Europe with commercial debut targeted for May 16 - Traders Union
Evolus Inc Stock (EOLS) Financials Data
Revenue
Net Income
Cash Flow
EPS
Evolus Inc Stock (EOLS) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| MOATAZEDI DAVID | See Remarks |
Mar 20 '26 |
Sale |
4.75 |
13,669 |
64,929 |
604,700 |
| MOATAZEDI DAVID | See Remarks |
Mar 16 '26 |
Option Exercise |
0.00 |
67,489 |
0 |
735,089 |
| MOATAZEDI DAVID | See Remarks |
Mar 17 '26 |
Sale |
4.89 |
116,720 |
570,562 |
618,369 |
| Avelar Rui | See Remarks |
Mar 16 '26 |
Option Exercise |
0.00 |
8,804 |
0 |
460,538 |
| Avelar Rui | See Remarks |
Mar 17 '26 |
Sale |
4.89 |
29,996 |
146,629 |
430,542 |
| MOATAZEDI DAVID | See Remarks |
Dec 22 '25 |
Sale |
7.15 |
10,539 |
75,361 |
354,388 |
| Avelar Rui | See Remarks |
Dec 22 '25 |
Sale |
7.15 |
2,261 |
16,168 |
356,821 |
| Yamagishi-Dressler Tomoko | Chief Marketing Officer |
Aug 22 '25 |
Sale |
7.51 |
5,722 |
42,972 |
89,949 |
| Stewart Brady | Director |
Aug 15 '25 |
Buy |
6.82 |
30,000 |
204,486 |
88,629 |
1.03%
0.14%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):